GeneFormatics

About GeneFormatics

GeneFormatics, Inc. operated as a biotechnology firm with a focus on structural proteomics, founded in 1998 in San Diego, California. The company specialized in developing novel methods for predicting protein function to accelerate the identification of biologically relevant targets from large-scale genomic sequence data.

The core of GeneFormatics' business was its proprietary technology platform that combined protein structure prediction, functional analysis, and computer-aided molecular design. This platform utilized algorithms to deduce a protein's function from its structural information, a critical step in early-stage drug discovery. The company's "function first" approach involved using in-silico methods to predict protein functions and prioritize targets before engaging in 3-dimensional analysis, thereby narrowing the field for experimental work. This strategy was designed to mine and categorize vast amounts of genomic data efficiently. Their client base primarily consisted of pharmaceutical and biotechnology companies, to whom they offered services to accelerate and optimize the drug discovery process. The business model involved providing professional services and consulting, and it had established research collaborations with major pharmaceutical companies like Bristol-Myers Squibb and Schering-Plough Research Institute.

Over its lifespan, GeneFormatics raised a total of $66.8 million through several funding rounds, including a Series A in February 2000 for $4 million, a Series B in October 2000 for $15 million, and a Series C in October 2001 for $24.8 million. Key investors included Aisling Capital, Bruker, Burrill & Co, CDIB Capital Group, and IBM Ventures. A significant milestone was a strategic partnership with Bruker companies to advance the development of experimental technologies for its structural proteomics platform. In May 2003, GeneFormatics was acquired by and merged with Structural Bioinformatics to form Cengent Therapeutics, a new entity focused on structure-guided drug discovery.